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ABSTRACT
Clinical chorioamnionitis continues to contribute to fetal and maternal morbidity and mortality.
Significant advances have been made in the last 20 years in understanding the pathophysiologic
processes leading to chorioamnionitis. This review addresses the history, incidence, pathophysiol-
ogy, host defenses, risk factors, diagnosis, and maternal and neonatal management of clinically
evident chorioamnionitis. After a detailed review of the physiologic processes leading to clinical
chorioamnionitis and sepsis, we present a modern management scheme designed to optimize peri-
natal outcome for both mother and fetus. (C) 1995 Wiley-Liss, Inc.
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ntrauterine infection, either antepartum or intra-
partum, continues to contribute to perinatal and
maternal morbidity and mortality. A number of
terms have been used to describe this condition
including clinical chorioamnionitis, intrapartum fe-
ver, amnionitis, amniotic-fluid infection, and in-
traamniotic infection. Unfortunately, these terms
have been used by different investigators to charac-
terize 3 separate clinical processes: 1) histologic
chorioamnionitis in the absence of clinical symp-
toms; 2) positive amniotic-fluid culture assessed at
the time of amniocentesis for preterm labor or pre-
mature rupture of the membranes; and 3) "clini-
cally evident" infection manifested by fever with
localizing signs on physical examination. This re-
view will address the history, incidence, patho-
physiology, host defenses, risk factors, diagnosis,
and management of intrauterine infection with an
emphasis on "clinically evident" infection.
Clinical chorioamnionitis is diagnosed in the
presence of clinical symptomatology: fever >38C
accompanied by uterine tenderness; maternal or re-
tal tachycardia; and malodorous, purulent amniotic
fluid. Labor may or may not be present and the
membranes may or may not be ruptured. Any of
these physical findings may be absent depending on
the severity and duration of the infection, virulence
and inoculum size of the organism, integrity of the
host defense mechanisms, and presence of masking
factors such as regional anesthesia. The diagnosis
should be confirmed by histologic examination of
the placenta. The clinical usefulness of obtaining
intrapartum amniotic-fluid cultures or placental
cultures after delivery remains unknown. In addi-
tion, the effect of intrapartum antibiotics on the
success rate of amniotic-fluid or placental cultures
remains unclear. However, if desired, the obstetri-
cian may, in the delivery room, manually separate
the amnion from the chorion and obtain a culture of
the fetal surface of the chorionic plate to optimize
the yield from placental cultures and minimize the
isolation of contaminant vaginal flora.
The presence of histologic chorioamnionitis does
not imply that clinical chovioamnionitis was present
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prior to delivery. Many authors have examined the
frequency with which histologic chorioamnionitis
is found in febrile and afebrile parturients. In one
of the largest prospectively evaluated series to date,
Mueller-Heubach et al. examined over 1,800 con-
secutive singleton placentas in a blinded fashion.
Standardized cuts of the chorionic plate were exam-
ined, but neither the membrane roll nor umbilical
cord was examined. I--Iistologic chorioamnionitis
was present in 18% of the term deliveries vs. 32%
of the preterm deliveries. Other series have noted
the incidences of histologic chorioamnionitis to be
15%-80%, depending on the population and gesta-
tional age studied and whether the sections were taken
from the chorionic plate alone or from the chorion,
membrane roll, and umbilical cord. Grading classifi-
cations of the severity of the inflammatory infiltrate
have also varied considerably. Therefore, no defini-
tive conclusions can be made regarding the effect of
placental histology on fetal or neonatal prognosis.
However, 2 observations have been consistently noted
in the literature: severe histologic chorioamnionitis is
infrequently found in afebrile gravidas and, if funisi-
tis is present, severe chorioamnionitis will be found in
the chorionic plate and membrane roll.
HISTORICAL NOTES
In 1962, Russell and Amadeus
2 reviewed 131 con-
secutive cases of chorioamnionitis at a large obstet-
ric institution and noted a maternal death rate of
3.8% secondary to sepsis. Gibbs and Locke, in a
review of maternal deaths in Texas from 1969-
1973, reported that 10 of 501 maternal deaths were
secondary to chorioamnionitis. The Medical Society
ofNew Jersey Subcommittee on Maternal Mortality
4
reviewed 115 maternal deaths for the years 1985-
1989 and noted no maternal deaths secondary to chori-
oamnionitis and sepsis during a period in which ap-
proximately 500,000 live births were recorded. We
have observed no maternal deaths in a series of over
200 cases of clinical chorioamnionitis managed at our
tertiary-care institution from 1990-1994. It would
appear that advances in the understanding and man-
agement of chorioamnionitis along with improve-
ments in critical-care medicine have led to decreases
in the case fatality ratio for chorioamnionitis.
INCIDENCE
Obstetric texts have stated in the past that the inci-
dence of clinical chorioamnionitis is approximately
1-2%. Retrospective series at large indigent insti-
tutions in the 1970s revealed a 0.5-0.8% incidence
of clinical chorioamnionitis. Conversely, 2 pro-
spective series in the mid-1980s at teaching hospi-
tals noted incidences of 4.2 and 10.5%.
5,6 It is
unclear if these reported differences reflect actual
changes in the incidence of the disease as a result of
evolving obstetric practices (such as frequent inva-
sive fetal monitoring during the active manage-
ment of labor) or if they reflect the vagaries of
disease detection in retrospective vs. prospective
evaluations. The incidence of intrapartum chorio-
amnionitis varies according to the presence or ab-
sence of a number of classically described risk fac-
tors such as socioeconomic status, parity, duration
of ruptured membranes and labor, presence of in-
ternal fetal monitoring systems, gestational age at
delivery, number of vaginal examinations, and ab-
normalities in labor progression (see Risk Factors
below).
Infrequently, clinical chorioamnionitis results
from an invasive procedure such as amniocentesis,
chorionic-villus sampling, cordocentesis, or cer-
clage. The risk of clinical infection after amniocen-
tesis or chorionic-villus sampling is quite low, and
large series have noted incidences of approximately
in 1,000 procedures.
7 These infections typically
lead to pregnancy loss at a pre-viable gestation.
More extensive and time-consuming procedures
such as cordocentesis and intravascular transfusion
may be associated with infection rates of 1% to as
high as 5%.8 Elective prophylactic cerclage is gen-
erally considered to carry an infectious complica-
tion rate of 1-2%, while emergency cerclage place-
ment in the face of advanced cervical dilation and
bulging membranes may be associated with rates of
clinical chorioamnionitis as high as 25%. 9’10
PATHOPHYSIOLOGY
Clinical chorioamnionitis typically results from the
ascension of organisms from the vagina to the uter-
ine cavity after rupture of the membranes. Occa-
sionally, infection may occur because of hematoge-
nous dissemination of bacteria through the
bloodstream. For example, Listeria monocytogenes
has been reported to result from a blood-borne
infection after the ingestion ofcontaminated food.
11
Even more rarely, bacterial infection with organ-
isms such as Streptococcus pyogenes (group A strepto-
coccus), Neisseria gonorrhoeae, Campylobacter, and
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TABLE I. Distribution of microbes in 408 cases of
intraamniotic infection
Microbe No. %
Group B streptococci 60 15
Enterococci 22 5
Escherichia coli 33 8
Gardnerella vaginalis 99 24
Other aerobic gram-negative rods 21 5
Peptostreptococci 38 9
Bacteroides bivius 120 29
Fusobacterium sp. 23 6
Bacteroids fragilis 14 3
Mycoplasma hominis 125 31
Ureaplasma urealyticum 195 47
aData from Gibbs et al.
is
Streptococcus pneumoniae may occur in the absence
of labor or ruptured membranes if they ascend to
the amniotic cavity,
lz-14 It is unclear if these types
of infections reflect a subcategory of high-virulence
organisms or an alteration in local or systemic host
factors.
The bacterial composition of the amniotic fluid
in clinical chorioamnionitis associated with rup-
tured membranes appears to be polymicrobial. In
1982, Gibbs et al.
is reported the microbiologic
constituents of the amniotic fluid of patients with
clinical chorioamnionitis and matched controls.
Seventy percent of the patients with clinically evi-
dent infection had >100 CFU/ml of virulent or-
ganisms compared with only 8% of the controls.
The most common organisms noted were anaerobes
and group B streptococci. Gravett et al.
6 have
noted similar findings. The distribution of organ-
isms in over 400 cases of chorioamnionitis can be
seen in Table 1.
Interestingly, pregnancies with chorioamnioni-
tis resulting in the births of newborns <2,500 g
have been noted to contain significantly higher fre-
quencies of anaerobic organisms such as Bacteroides
bivius and Fusobacterium than term controls but
similar frequencies of gram-negative enterics and
group B streptococci. One can speculate that these
anaerobes may asymptomatically ascend to the uter-
ine cavity and initiate preterm labor and delivery
through deciduitis and expression of humoral fac-
tors such as tumor necrosis factor (TNF), interleu-
kins, and other cytokines. Bejar et al.
17 have noted
that phospholipase A2 activity may be highest in
anaerobic isolates and that this resultant activity
could result in the generation of prostaglandins
from the decidua or chorion and lead to uterine
contractions.
Even though amniotic-fluid cultures are posi-
tive for group B streptococci or E. coli in only 20%
of patients with clinical chorioamnionitis, these 2
organisms account for two-thirds of maternal and
neonatal bacteremia.
18 When either group B strep-
tococci or E. coli is present in the amniotic fluid,
25-33% of the mothers or neonates will manifest
bacteremia. Rarely will anaerobic bacteria be found
in the maternal or neonatal bloodstream. It is un-
clear if the low incidence of anaerobic bacteremia
reflects the true clinical state or greater difficulty in
the laboratory in detecting these organisms.
In addition to the initiation of labor, chorioam-
nionitis may lead to bacteremia, adult respiratory
distress syndrome (ARDS), disseminated intravas-
cular coagulation (DIC), acute renal failure, or
septic shock secondary to the production of endo-
toxin and various humoral factors and cytokines
(Fig. 1). The elucidation of these humoral factors
during the past 10 years has greatly increased our
understanding of the pathogenesis of the sepsis syn-
drome. Arachidonic-acid metabolites such as the
leukotrienes, prostaglandins, and thromboxanes
have complex effects on cellular physiology.
Thromboxane A2 has been shown to cause platelet
and neutrophil aggregation and activation, vaso-
constriction of vascular beds, and bronchoconstric-
tion. Prostacyclin has been shown to inhibit platelet
adhesiveness, stimulate the release of cytokines, in-
hibit gastric-acid secretion, and relax smooth mus-
cle.
19 Increased levels of TNF and interleukin-1
are associated with increased mortality rates in sep-
tic shock. Initial investigations into the use of anti-
cytokine antibodies in the management of sepsis
have been encouraging. Randomized control trials
have shown improvements in survival when septic
patients received anti-TNF antibody, interleukin-6
receptor antagonist, and anti-endotoxin antibod-
ies.z However, these data must be considered pre-
liminary, and further research is still needed.
HOST DEFENSES
It is unclear if amniotic fluid contains bacteriostatic
or bacteriocidal substances. The simple empiric ob-
servation that clinical chorioamnionitis is an infre-
quent event in patients with intact membranes led
early investigators to presume that amniotic fluid
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Fig. I. Pathophysiology of multiorgan failure in chorioamnionitis.
contains antibacterial agents. In addition, studies
have demonstrated that a strong correlation exists
between the degree of oligohydramnios after pre-
term premature rupture ofthe membranes and clin-
ical chorioamnionitis.
21 Investigators have at-
tempted to document the presence of chemotactins,
lysozymes, immunoglobulins, transferrin, and a
zinc-peptide complex. None of these has conclu-
sively or repeatedly been shown to modify clinical
inf’ection.
22
RISK FACTORS
The classically described risk factors for clinical
chorioamnionitis are summarized in Table 2. In
1989, Soper et al.
6 and Newton et al.
5 prospec-
tively evaluated risk factors by multiple regression
analysis. Interestingly, several of the "established"
risk factors noted in Table 2 did not meet the
criteria for independent risk status. The rates of
clinical chorioamnionitis were noted to be 4% and
10%, respectively, and these high rates may have
contributed to the elimination of some factors clas-
sically associated with clinical chorioamnionitis.
These investigators established probability curve
paradigms that may serve as models for future re-
TABLE 2. Traditional risk factors for
intraamniotic infection
Duration of rupture of membranes
Internal fetal monitoring
Number of vaginal examinations
Duration of labor
Young maternal age
Low gravidity and parity
Low socioeconomic status
Requirement of oxytocin augmentation
search (Tables 3 and 4). Their observation that
most patients developing clinical chorioamnionitis
entered high-risk categories for several hours prior
to the actual manifestation of chorioamnionitis is
especially intriguing, as intervention during the
prodromal period could theoretically modify the
infectious process.
DIAGNOSIS
The diagnosis of clinical chorioamnionitis is sug-
gested by the presence of fever in a gravid patient
without evidence of urinary, respiratory, or other
localized infection. Ruptured membranes are typi-
cally present but are not essential for the diagnosis
to be made. Most authors have noted that the fre-
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TABLE 3. Probability of intraamniotic infection
given varying combinations of risk factors
Duration of
No. of ruptured Total
vaginal membranes labor
examinations (h) (h) Probability
2 5.25 6.0 0.03
5 12.00 16.0 0.16
6 16.00 21.0 0.32
8 21.75 29.0 0.63
13 88.00 29.0 0.95
aData from Soper et al.
TABLE 4. Criteria predicting a probability of
intraamniotic infection of 20./o or greater
Internal Membrane
monitoring rupture
(h) (h)
0 with > 60
with > 48
2 with > 36
3 with > 28
4 with > 14
5 with > 6
6 with > 6
aData from Newton et al.
quency ofassociated physical findings is low. I-Iauth
et al.
23 noted, in more than 100 cases of clinical
chorioamnionitis, that fever was present in >99%,
fetal tachycardia in 82%, maternal tachycardia in
19%, uterine tenderness in 16%, and malodorous
amniotic fluid in 9%. The diagnosis is established
clinically. Laboratory assessments such as leukocy-
tosis with a left shift, increased C-reactive protein,
leukocyte esterase assays, and gas chromatography
are nonspecific, insensitive, or expensive and cum-
bersome, and therefore not clinically useful. Infre-
quently, the diagnosis may be suggested in an afe-
brile, laboring gravida by signs of fetal distress
such as fetal tachycardia and decreased variability.
Rarely, the diagnosis will be made in an afebrile,
nonlaboring patient with intact membranes who
presents with decreased fetal movement and an ab-
normal biophysical assessment.
MANAGEMENT
The management of clinical chorioamnionitis must
include an assessment of the clinical severity of the
maternal and fetal infection, an awareness of the
likelihood of vaginal delivery, an estimation of the
anticipated timing of the delivery, and an anticipa-
tion of the postpartum and postnatal complications
in chorioamnionitis (Fig. 2). Though the risk of
maternal death due to chorioamnionitis in modern
obstetrics is extremely low, the risk for significant
morbidity is real. As previously discussed, endo-
toxemia may result in endothelial damage and lead
to hypoxemia due to a capillary leak syndrome.
Bacteremia may lead to septic shock with resultant
ARDS, DIC, and acute renal failure. Close atten-
tion must be paid to the volume status and clinical
signs of disease progression such as hypotension,
tachycardia, tachypnea, and oliguria. The manage-
ment of these complications must be undertaken
with the appropriate critical-care consultation in an
intensive care setting where hemodynamic observa-
tions and manipulations may be made. The inter-
ested reader is directed to other works regarding
the management of these conditions, as a descrip-
tion of them is beyond the scope of this review.
The initial laboratory assessment should include
blood and urine cultures, CBC and differential,
and serum chemistries including BUN and creati-
nine. Maternal blood cultures are recommended,
as up to 10% of patients will exhibit bacteremia.
24
Coagulation studies should be performed if throm-
bocytopenia or a bleeding diathesis is evident. Con-
tinuous fetal heart rate monitoring of all viable
fetuses should be initiated at the time of diagnosis.
Fetal tachycardia may be a sign of fetal sepsis or
may simply reflect an appropriate cardiovascular
response to endogenous maternal pyrogens such as
the interleukins and TNF. The loss of variability
typically seen at the fetal heart rate baselines of
> 180 beats/min will prevent the obstetrician from
making an accurate assessment of fetal acid base
status, and serial scalp samplings may be required
to document that acidosis is not developing. It has
been hypothesized that cord-blood gases indicating
pre-acidosis or a mild metabolic acidosis may be a
marker for neonatal bacteremia, but investigators
testing this hypothesis have not been able to validate
this theory, zs
Infected fetuses can rapidly decompensate dur-
ing labor. For example, at the time of the mother’s
presentation to the labor floor, the fetus may ex-
hibit a fetal heart tracing with normal variability,
baseline, and periodic changes. After several hours
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Fig. 2. Evaluation and management of clinical chorioamnionitis.
of labor, the fetus may manifest a new onset base-
line tachycardia with decreased variability but no
decelerations. Thirty minutes later, persistent late
decelerations may be noted without a change in
variability. Sixty minutes after the first tracing,
there may be absent variability. At delivery or
shortly thereafter, such a neonate may be septic,
clinically depressed, and subsequently developmen-
tally delayed.
Clinical chorioamnionitis has been associated
with an increased risk for abnormal labor progres-
sion.
z6 However, initial studies did not explain
whether the chorioamnionitis causes or results from
a protracted labor. Silver et al.
2v compared the
labor progress in afebrile, laboring nulliparas at
term with and without positive intraamniotic cul-
tures obtained through serial intrauterine pressure
catheter aspirations. Nulliparas with persistent
high-virulent isolates (but no evidence of clinical
chorioamnionitis) had significantly lower cervical
dilation rates, despite a higher oxytocin infusion
rate, and a higher cesarean delivery rate. They
suggested that the presence ofhigh-virulence bacte-
ria in the amniotic fluid predisposes to hypocon-
tractility and poor cervical dilation. In vitro evi-
dence to support this suggestion has been reported
by Leek et al.
28 They noted that a number of dif-
ferent bacterial isolates reduced or eradicated the
spontaneous motility of myometrial strips in vitro.
In addition, they noted that physiologic doses of
oxytocin were unable to overcome this inhibitory
effect.
Once a diagnosis of clinical chorioamnionitis has
been established, delivery is indicated to remove
the infected fetus and placenta from the uterus and
reduce the risk of sepsis to the fetus and mother.
However, the optimal time frame in which to de-
liver the fetus is unknown. Few data exist to de-
scribe the most appropriate interval from either
diagnosis to delivery or antibiotic administration to
delivery. Although clinicians in the 1970s recom-
mended that delivery be effected within 1-2 h after
the diagnosis, recent data have not supported this
recommendation. Gibbs et al.
29 studied 171 gravi-
das with clinical chorioamnionitis and noted no
differences in the percentages of pregnancies with
maternal or neonatal bacteremia when the diagno-
sis-to-delivery intervals were arbitrarily broken into
4-h increments. However, < 10% of their fetuses
were delivered >12 h after the diagnosis. Hauth
et al.
23 studied 103 gravidas with clinical chorio-
amnionitis in whom no differences in neonatal out-
come were noted when the diagnosis-to-delivery
intervals were increased from h up to 10 h.
Again, however, only 2% of their patients were
delivered after 10 h. It appears from the above data
that a diagnosis-to-delivery interval of up to 12 h is
not associated with increased neonatal morbidity
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(assuming that the mother is receiving parenteral
antibiotics). However, the risks to the fetus, if a
delay beyond 12 h occurs, are simply unknown. In
the only prospective, randomized control trial to
date regarding the therapeutic management of clin-
ical chorioamnionitis, Gibbs et al.
3 excluded pa-
tients who were <4 cm dilated at the time of diag-
nosis for fear of a prolonged labor course and
resultant adverse perinatal outcome.
Until the late 1980s, no consensus of opinion
existed as to the most opportune time to initiate
antibiotics after making the diagnosis of clinical
chorioamnionitis. Prior to this time, many obstetri-
cians chose to defer antibiotics until after the cord
was clamped so as not to interfere with the diagnosis
and management of the neonate. Based on 2 retro-
spective studies and prospective study at large
indigent institutions, popular opinion appears to
have changed. Sperling et al.
31 published a retro-
spective examination of 257 term gravidas with
clinical chorioamnionitis and noted that the inci-
dence of neonatal bacteremia was significantly lower
in newborns who received intrapartum antibiotics
vs. those receiving antibiotics after cord clamping
(2.8% vs. 20%, respectively). Gilstrap et al.
2
noted a similar trend but without statistical signifi-
cance. In these retrospective studies, the patients
who did not receive antibiotics until after delivery
had significantly lower maximum temperatures and
shorter diagnosis-to-delivery intervals. These facts
serve to confirm the efficacy of intrapartum treat-
ment, since the post-delivery treatment group
should have had even lower neonatal sepsis rates.
The antibiotics used in these studies typically in-
cluded a penicillin or derivative (with or without
an aminoglycoside) or a second-generation ceph-
alosporin.
Gibbs et al. have published the only random-
ized, controlled trial to date evaluating the useful-
ness of intrapartum antibiotics in the prevention of
neonatal sepsis. The trial was stopped after only
half of the planned patients were enrolled because
an independent safety committee’s interim analysis
had noted statistically significant differences in the
rates of neonatal sepsis and pneumonia between the
treated and untreated groups (0% vs. 33%). No
differences in Apgar scores were noted.
Although no data exist to prove or disprove the
usefulness of anaerobic coverage during the intra-
partum treatment of chorioamnionitis, the rarity of
anaerobic neonatal sepsis has precluded the routine
use of intrapartum clindamycin or an equivalent
antibiotic. However, it is commonplace at our in-
stitution to add clindamycin during the intrapar-
turn period if the mother shows clinical signs of
deterioration or high fever (temperature >39%).
The ideal antibiotic regimen for intrapartum usage
is unknown at this time. Antibiotics cross the pla-
centa in varying concentrations, but the measure-
ment of antibiotic levels in various maternal and
fetal compartments suggests that ampicillin and gen-
tamycin have high cord blood/maternal blood ra-
tios. In our institution, we typically administer
2 g of ampicillin every 6 h and 100 mg of genta-
mycin every 8 h (after a 120-mg loading dose) to
gravidas with suspected chorioamnionitis. We ad-
minister 900 mg of clindamycin every 8 h instead
of ampicillin if the patient reports a penicillin al-
lergy. Although ampicillin and gentamycin are con-
sidered the "gold standard," newer broad-spectrum
agents such as ticarcillin or ampicillin-sulbactam
demonstrate similar bacterial coverage. Neverthe-
less, large series have not yet been reported to en-
sure their clinical equivalence.
Studies have repeatedly demonstrated that cesar-
ean delivery increases the maternal morbidity in
clinical chorioamnionitis. Koh et al.
34 reported
a 43% incidence of endometritis after cesarean de-
livery vs. only an 11% incidence after vaginal
delivery. Gogois reported that 13 of 14 maternal
deaths as a result of chorioamnionitis occurred after
cesarean delivery. Gravidas with clinical chorioam-
nionitis who are delivered abdominally are at in-
creased risk for postoperative peritonitis, postpar-
tum endometritis, septic pelvic thrombophlebitis,
ovarian vein thrombosis, and wound infection.
Yonekura et al.
z6 reported no difference in post-
partum morbidity when comparing transperitoneal
vs. extraperitoneal cesarean delivery. IV antibiotics
should be continued after cesarean delivery until
fever has been absent for 24-48 h and the clinical
signs and symptoms are resolving. Additional
anaerobic coverage such as that obtained with clin-
damycin or metronidazole should be added after
cord clamping if not previously administered dur-
ing the intrapartum period. This additional cover-
age is given to ensure adequate coverage of the
anaerobic organisms traditionally associated with
postpartum endometritis. The lower incidence of
postpartum endometritis after a vaginal delivery
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makes the need for the continuation of IV antibiot-
ics after vaginal delivery less certain.
Recent studies have demonstrated that there may
be no need for a course of oral antibiotics after a
patient is discharged from the hospital in the case of
an uncomplicated chorioamnionitis or endometri-
tis. 37’38 Gravidas presenting with bacteremia, im-
munosuppression, HIV positivity, concurrent
wound or other infection, abscess, or septic pelvic
phlebitis have been excluded from these studies.
These patients deserve full courses of the tradition-
ally described antibiotic regimens.
The treatment of clinical chorioamnionitis in the
gravida with ruptured membranes using antibiotics
alone and without an effort to deliver her poses
risks to both mother and fetus. However, the suc-
cessful eradication of clinical chorioamnionitis with-
out delivery in gravidas with intact membranes and
listeriosis has been reported in all 3 trimesters.
39-41
In the absence of symptoms of an upper respiratory
infection, we believe that the gravida presenting
with fever, a flu-like illness, and uterine contrac-
tions can be maintained on IV ampicillin until
blood-culture negativity has been confirmed and
listeriosis ruled out. Pregnant patients should avoid
the ingestion of raw meats, dairy products such as
soft cheeses (brie or feta), and ready-to-eat pack-
42 aged meats such as pats and sandwich meats.
NEONATAL MANAGEMENT
Chorioamnionitis presents a number of threats to
the fetus and neonate. Sepsis rates of 1-6% are
seen, and congenital pneumonia may be found in as
many as 25% of neonates.24’4 The mortality rate
of neonatal septicemia has been described as 25-
50%, although more recent series have noted lower
rates. Morales et al.
43 reported that mental and
physical development scores were not different in
preterm gestations complicated by chorioamnioni-
tis after controlling for ARDS, intraventricular
hemorrhage, and birth weight. However, because
premature newborns delivered through a clinically
infected uterus exhibit higher rates of ARDS and
intraventricular hemorrhage vs. gestational age-
and weight-matched infants, their physical and de-
velopmental scores and mortality rates will be worse
44 than their noninfected counterparts.
Although intrapartum antibiotics have been
touted as a method of reducing the risk of neonatal
sepsis, they by no means reduce this risk to zero. In
a retrospective series of nearly 100 newborns posi-
tive for early-onset group B streptococcal bactere-
mia, 19% of these babies had received intrapartum
antibiotics at a median age of 4 h prior to deliv-
45 ery. Seventy-two percent of these newborns were
born to mothers suspected ofhaving chorioamnion-
itis. In addition, both the large data set from
Gilstrap et al.
2 and a small series from McDuffie
et al.
46 suggest that intrapartum ampicillin may
result in neonatal sepsis due not to group B strepto-
coccus, but rather to more virulent and resistant
organisms. Intrapartum chemoprophylaxis has
never been to shown to prevent late-onset group B
streptococcal infection.
The management of a term neonate delivered
through an infected uterus is controversial. Wiswell
et a1.,47 in a survey of 75 teaching institutions,
noted that only 30% of the respondents initiate
therapy of the asymptomatic term neonate and only
70% perform a laboratory or x-ray evaluation. At
our institution, we evaluate the asymptomatic term
neonate delivered through a clinically infected
uterus with a CBC and blood culture immediately
after birth. Antibiotics are not begun if the mother
received intrapartum antibiotics unless the neonate
manifests signs of sepsis or the blood culture re-
turns positive. Asymptomatic preterm newborns
are treated with a 7-10 day course of IV ampicillin
and gentamycin for presumptive sepsis. Symptom-
atic newborns (whether term or preterm) receive a
10-21 day course depending on the infant’s clinical
course and culture results.
SUMMARY
Clinical chorioamnionitis continues to be associated
with significant neonatal and maternal morbidity
and mortality. Research during the last 20 years has
enabled us to characterize the epidemiology and
molecular pathophysiology leading to this infec-
tion. Unfortunately, we currently cannot establish
the diagnosis until the infection is clinically evi-
dent, resulting in alterations in the normal mater-
nal-fetal homeostasis. Current topics of research
include assessments of primary prevention such as
vaccination with group B streptococcal antigen,
early identification of at-risk parturients using clin-
ical paradigms or rapid detection antigen assays,
and determination of the optimal type and mode of
delivery of antibiotics.
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